Bath & Body Works Reports 3% Sales Increase

Bath & Body Works, Inc. (NYSE: BBWI) has reported its third quarter 2024 results, with net sales coming in at $1.6 billion, marking a 3% increase over the same period last year. Earnings per diluted share for the third quarter were reported at $0.49, exceeding the company's guidance. However, this figure represents a slight decrease from the $0.52 reported in the third quarter of 2023.

The company's third quarter operating income stood at $218 million, down from $221 million in the third quarter of 2023. Net income for the third quarter of 2024 was $106 million, a decrease from $119 million in the same period last year.

Looking ahead, Bath & Body Works expects a decline in net sales for the 13-week fourth quarter of 2024, ranging between 6.5% and 4.5%, compared to the 14-week fourth quarter of 2023. The company also anticipates fourth quarter earnings per diluted share to be between $1.94 and $2.07, down from $2.55 in the fourth quarter of 2023.

For the full fiscal year 2024, the company has revised its guidance, now expecting net sales to range between a decline of 2.5% to a decline of 1.7% compared to fiscal 2023. Earnings per diluted share for the full year 2024 are now expected to be between $3.46 and $3.59, compared to $3.84 in 2023. Adjusted earnings per diluted share for the full year 2024 are expected to be between $3.15 and $3.28, down from $3.27 in fiscal 2023.

It's worth noting that the company's full-year guidance includes the anticipated impact of $400 million of cash deployed towards share repurchases.

Following these announcements, the company's shares moved 16.8%, and are now trading at a price of $35.87. For the full picture, make sure to review Bath & Body Works's 8-K report.

The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.

IN FOCUS